Item 7.01. Regulation FD Disclosure.
Neurotrope, Inc. has prepared an investor presentation to be
presented to members of the investment community, a copy which is attached to this Current Report on Form 8-K as Exhibit 99.1.
In accordance with General Instruction B.2 on Form 8-K, the
information set forth in this Item 7.01 and the investor presentation attached to this report as Exhibit 99.1 is “furnished”
and shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended,
or otherwise subject to the liabilities of that Section, nor shall such information be deemed incorporated by reference in any
filing under the Securities Exchange Act of 1934, as amended, or the Securities Act of 1933, as amended.
The investor presentation attached hereto as Exhibit 99.1 contains
certain statements that may be deemed to be “forward-looking statements” within the meaning of Section 27A of the Securities
Act of 1933 and Section 21E of the Securities Exchange Act of 1934. In some cases, these forward-looking statements can be identified
by the use of forward-looking terminology, including the terms “believes,” “estimates,” “anticipates,”
“expects,” “plans,” “intends,” “may,” “could,” “might,”
“will,” “should,” “approximately” or, in each case, their negative or other variations thereon
or comparable terminology, although not all forward-looking statements contain these words. They appear in a number of places throughout
the presentation and include statements regarding our intentions, beliefs, projections, outlook, analyses or current expectations
concerning, among other things, our ongoing and planned discovery and development of drugs targeting Alzheimer’s disease
and other cognitive and neurodevelopmental disorders, the strength and breadth of our intellectual property, our ongoing and planned
preclinical studies and clinical trials, the timing of and our ability to make regulatory filings and obtain and maintain regulatory
approvals for our product candidates, the degree of clinical utility of our products, particularly in specific patient populations,
expectations regarding clinical trial data, our results of operations, financial condition, liquidity, prospects, growth and strategies,
the length of time that we will be able to continue to fund our operating expenses and capital expenditures, our expected financing
needs and sources of financing, the industry in which we operate and the trends that may affect the industry or us.
By their nature, forward-looking statements involve risks and
uncertainties because they relate to events, competitive dynamics, and healthcare, regulatory and scientific developments and depend
on the economic circumstances that may or may not occur in the future or may occur on longer or shorter timelines than anticipated.
Although we believe that we have a reasonable basis for each forward-looking statement contained in the presentation, we caution
you that forward-looking statements are not guarantees of future performance and that our actual results of operations, financial
condition and liquidity, and the development of the industry in which we operate may differ materially from the forward-looking
statements contained in the presentation as a result of, among other factors, the factors referenced in the “Risk Factors”
section of our Annual Report on Form 10-K filed with the Securities and Exchange Commission on March 10, 2017 and the “Risk
Factors” sections of our Quarterly Reports on Form 10-Q filed with the Securities and Exchange Commission on May 12, 2017,
August 8, 2017 and November 3, 2017, respectively. In addition, even if our results of operations, financial condition and liquidity,
and the development of the industry in which we operate are consistent with the forward-looking statements contained in the presentation,
they may not be predictive of results or developments in future periods. Any forward-looking statements that we make in the presentation
speak only as of the date of such statement, and we undertake no obligation to update such statements to reflect events or circumstances
after the date of the presentation, except as required by law.
You should read carefully our “Cautionary Note Regarding
Forward-Looking Statements” and the factors described in the “Risk Factors” sections of our Annual Report on
Form 10-K and Quarterly Reports on Form 10-Q to better understand the risks and uncertainties inherent in our business.